HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

California Air Resources Board will hold public hearing March 18 in Sacramento, Calif. to consider variance applications from Gillette and Procter & Gamble. Variances are granted to manufacturers who prove they cannot comply with volatile organic compound regulations due to extraordinary reasons beyond their reasonable control. Gillette has applied for a variance from the 40%VOC limit for aerosol antiperspirants and the 0% limit for aerosol deodorants. P&G has applied for a variance from the 40% VOC limit for aerosol antiperspirants and the 75% limit for personal fragrance products with 20% or less fragrance. Separately, CARB extends due date for submission of 2003 Consumer & Commercial Products Survey to April 1 from original deadline of March 15...

You may also be interested in...

Antiperspirant Ingredient Shortage Prompts VOC Variance Requests

A spike in demand for the ingredient hydro-fluorocarbon 152a, manufactured by DuPont as Dymel 152a and used by antiperspirant manufacturers as a full or partial replacement to hydrocarbon propellants, has led some manufacturers to apply for variance applications in the state of California

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab

Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts